Dexcom CGM Systems: Complete Product Lineup

Dexcom is the leading dedicated CGM manufacturer in the United States, producing real-time continuous glucose monitors for people with diabetes and, more recently, over-the-counter biosensors for general wellness. Dexcom holds 3 FDA-cleared CGM product lines and supplies sensors to major insulin pump manufacturers for integrated closed-loop systems.

Dexcom produces 3 distinct CGM product lines in 2026: the prescription Dexcom G7 platform (available in 10-day and 15-day variants) and the over-the-counter Dexcom Stelo biosensor. The G7 platform is the CGM component in 3 of the 4 major automated insulin delivery systems available in the United States, including the Omnipod 5, Tandem t:slim X2 with Control-IQ, and Tandem Mobi. The Stelo launched in 2024 as Dexcom's first product not requiring a prescription, targeting the wellness and prediabetes market at $49 to $99 per month. Dexcom sensors use electrochemical glucose oxidase technology and are factory-calibrated, requiring no fingerstick confirmations for treatment decisions.

With a market capitalization exceeding $40 billion, Dexcom (NASDAQ: DXCM) is the largest pure-play CGM company in the world. Founded in 1999 in San Diego, California, Dexcom has secured more than 1,000 patents related to continuous glucose monitoring technology. The company invested $668 million in R&D in 2024 alone, focusing on longer sensor life, smaller form factors, and expanding indications beyond diabetes.